Results 191 to 200 of about 25,303 (250)

Proprotein convertase subtilisin/kexin type 9: a promising marker of cardiovascular risk in post-menopausal diabetic women in primary prevention. [PDF]

Front Med (Lausanne)
Rottura M, Barbieri MA, Siniscalchi C, Di Micco P, Drago SFA, Gigliotti De Fazio M, Cicero AFG, Fogacci F, Armentaro G, Sciacqua A, Arcoraci V, Irrera N, Imbalzano E.   +12 more
europepmc   +1 more source

A Pre-Clinical Study on the Use of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor PEP 2-8 to Mitigate Ischemic Injury in a Rat Marginal Donor Model. [PDF]

Int J Mol Sci
Grignano MA, Gregorini M, Barisione C, Ivaldo C, Verzola D, Rumeo N, Malabarba S, Mimmi MC, Montatixe Fonseca EC, Viglio S, Iadarola P, Islami T, Pattonieri EF, Ceccarelli G, Picciotto D, Pratesi G, Viazzi F, Stea ED, Arbustini E, Esposito P, Rampino T.   +20 more
europepmc   +1 more source

Correction: Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression. [PDF]

J Biol Chem
Wang D, Yang X, Chen Y, Gong K, Yu M, Gao Y, Wu X, Hu H, Liao C, Han J, Duan Y.   +10 more
europepmc   +1 more source

The proprotein convertase FURIN is a novel aneurysm predisposition gene impairing TGF-β signalling. [PDF]

Cardiovasc Res
He Z, IJpma AS, Vreeken D, Heijsman D, Rosier K, Verhagen HJM, de Bruin JL, Brüggenwirth HT, Roos-Hesselink JW, Bekkers JA, Huylebroeck DFE, van Beusekom HMM, Creemers JWM, Majoor-Krakauer D.   +13 more
europepmc   +1 more source

<i>Proprotein Convertase Subtilisin</i>/<i>Kexin Type 9</i> (<i>PCSK9</i>) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia. [PDF]

Int J Mol Sci
Woźniak E, Woźniak A, Pawlos A, Broncel M, Satała J, Bukowska B, Gorzelak-Pabiś P.   +6 more
europepmc   +1 more source

The correlation between proprotein convertase subtilisin/kexin type 9 and adiponectin in the progression from prediabetes to type 2 diabetes mellitus. [PDF]

Sci Rep
Gu JX, Wang K, Zhang AM, Yin Y, Li SS, Zhang N, Qin L, Wang CY, Pei L, Jia M, Su M.   +10 more
europepmc   +1 more source

Efficacy and safety of different proprotein convertase subtilisin/kexin type 9 inhibitors in the general population and solid organ transplant recipients: a network meta-analysis. [PDF]

Front Pharmacol
Luo B, Sun Z, Luo H.
europepmc   +1 more source

Multimodal assessment of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors combined with statins for regulating coronary artery plaque regression in patients with chronic/acute coronary syndrome: A meta-analysis. [PDF]

J Int Med Res
Yuan D, Cheng T, Cao Z, Wang F, Wang Y.
europepmc   +1 more source

Successful use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Hypertriglyceridemia-induced Acute Pancreatitis: A Case Report. [PDF]

Curr Cardiol Rev
Qi R, Liu H, Li X, Chen M.
europepmc   +1 more source

Congenital Proprotein Convertase 1/3 Deficiency Causes Malabsorptive Diarrhea and Other Endocrinopathies in a Pediatric Cohort

Gastroenterology, 2013
BACKGROUND & AIMS Proprotein convertase 1/3 (PC1/3) deficiency, an autosomal-recessive disorder caused by rare mutations in the proprotein convertase subtilisin/kexin type 1 (PCSK1) gene, has been associated with obesity, severe malabsorptive diarrhea,
Michael Yourshaw, Iris Lindberg, Senta Georgia   +2 more
exaly   +2 more sources